Literature DB >> 22042962

Therapy for pediatric brain tumors and the risk of growth hormone deficiency.

Charles Sklar, Suzanne Wolden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22042962     DOI： 10.1200/JCO.2011.38.9833

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.

Authors:  Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

2.  Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study.

Authors:  Peter D Inskip; Lene H S Veiga; Alina V Brenner; Alice J Sigurdson; Evgenia Ostroumova; Eric J Chow; Marilyn Stovall; Susan A Smith; Rita E Weathers; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Charles A Sklar; Jay H Lubin
Journal:  Radiat Res       Date:  2018-05-15       Impact factor: 2.841

3.  Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.

Authors:  Haroon Hasan; Fuchsia Howard; Steven G Morgan; Daniel L Metzger; Andrea C Lo; Karen Goddard; Sabrina Gill; Michelle Johnson
Journal:  Healthc Policy       Date:  2014-02

4.  Premature Atherosclerotic Cardiovascular Disease in Childhood Cancer Survivors.

Authors:  Charles W Shepard; Julia Steinberger
Journal:  Prog Pediatr Cardiol       Date:  2015-11-17

5.  Exercise training improves vascular function and secondary health measures in survivors of pediatric oncology related cerebral insult.

Authors:  Treya M Long; Shoshana R Rath; Karen E Wallman; Erin K Howie; Leon M Straker; Andrew Bullock; Thomas S Walwyn; Nicholas G Gottardo; Catherine H Cole; Catherine S Choong; Louise H Naylor
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.